The Johnson & Johnson COVID-19 vaccine has been reported as safe and effective prevention of the virus.
While Johnson & Johnson originally planned to produce 12 million doses of the COVID-19 vaccine by the end of February, the production may be delayed until the end of April.
Johnson & Johnson has yet to confirm this delay. A report from Politico suggests they will meet their 2021 commitment to supply the doses of the vaccine.
"We remain in active discussions with regulators, including on the approval and validation of our manufacturing processes," the spokesperson said, according to an article from Politico.
Johnson & Johnson is partnered with Operation Warp Speed for the production of the COVID-19 vaccines. Warp Speed co-director, Moncef Slaoui, however, suggested that the production may indeed be delayed with less vaccines provided in February. However, more vaccines will be fulfilled by April.
According to an article from Bloomberg, there is great hope in the Johnson & Johnson vaccine. It has shown promising results in its one-shot dosage compared to other front-runner in COVID-19 vaccines, which consist of two-shots.
The progress of the Johnson & Johnson COVID-19 vaccine is being monitored due to its one-shot results. More tests and studies are being finalized to determine the effectiveness of the medicine for COVID-19. These studies should be ready by early February and then regulatory authorization by March. A single-shot vaccine can with mass-vaccination.
